AOD-9604
A modified hGH fragment (amino acids 176-191) studied in laboratory settings for fat metabolism, lipolysis, and body composition
About AOD-9604
AOD-9604 (CAS 221231-10-3) is a modified fragment of the C-terminus of human growth hormone, specifically amino acids 176-191. This synthetic peptide retains lipolytic signaling activity in adipocyte models while lacking the glycemic effects associated with full-length HGH.
AOD-9604 got its start in the late 1990s at Monash University in Australia. Researchers there were investigating whether a fragment of the growth hormone molecule could retain lipolytic signaling activity in adipocyte models without the glycemic and proliferative effects of the full-length protein.
The team identified that amino acids 176 to 191 of the growth hormone sequence exhibited lipolytic signaling in adipose tissue models without activating insulin or IGF-1-related growth pathways. They designated this fragment AOD-9604.
Since then, AOD-9604 has been the subject of numerous preclinical studies examining fat metabolism pathways. It caught the attention of labs worldwide looking for new ways to study lipolytic mechanisms. Today, it remains one of the most well-documented peptide fragments used in metabolic research.
Quick Facts
| CAS Number | 221231-10-3 |
|---|---|
| Molecular Formula | C₇₈H₁₂₃N₂₃O₂₃S₂ |
| Molar Mass | 1815.08 g/mol |
| Sequence | 16 amino acids (hGH 176-191) |
| Form | Lyophilized powder |
| Purity | 99%+ (HPLC verified) |
| Third-Party Testing | Freedom Diagnostics (COA included) |
| Storage | Room temp 3–4 months; refrigerate post-reconstitution |
| Price (from) | $75.00 USD |
| SKU | PF-AOD9604-5MG |
How AOD-9604 Works
Preclinical studies have examined AOD-9604's mechanism of action involving the same lipolytic signaling pathways as growth hormone, but without observed effects on glucose metabolism, insulin sensitivity, or tissue growth in laboratory models.
Beta-3 Adrenergic Receptor Activation
AOD-9604 selectively binds to and activates beta-3 adrenergic receptors located predominantly in adipose tissue. This activation triggers a cascade of intracellular signaling events that promote lipolysis through increased cAMP production and activation of hormone-sensitive lipase.
Enhanced Lipolytic Activity
The peptide significantly increases the rate of lipolysis by upregulating hormone-sensitive lipase and adipose triglyceride lipase activity in preclinical models. The released fatty acids are transported to mitochondria for beta-oxidation, generating ATP and supporting fat mobilization in research settings.
Lipogenesis Inhibition
AOD-9604 has been observed to inhibit de novo lipogenesis by downregulating key lipogenic enzymes including fatty acid synthase and acetyl-CoA carboxylase. This dual action creates a synergistic effect on body composition markers in preclinical research.
Frequently Asked Questions
- What is AOD-9604?
- AOD-9604 (CAS 221231-10-3) is a modified fragment of the C-terminus of human growth hormone, specifically amino acids 176-191. This synthetic peptide retains lipolytic signaling activity in adipocyte models while lacking the glycemic effects associated with full-length HGH.
- What is the CAS number for AOD-9604?
- The CAS number for AOD-9604 is 221231-10-3.
- What purity is Peptide Foundry's AOD-9604?
- Peptide Foundry's research peptides are manufactured to 99%+ purity. Every batch is verified by an independent third-party laboratory (Freedom Diagnostics) using high-performance liquid chromatography (HPLC) for purity and identity, Limulus amebocyte lysate (LAL) assay for bacterial endotoxin, and inductively coupled plasma mass spectrometry (ICP-MS) for heavy-metal contamination. A Certificate of Analysis is published for every product and batch.
- How should AOD-9604 be stored?
- Lyophilized (freeze-dried) peptides are stable at room temperature for 3–4 months. Once reconstituted with bacteriostatic water, store refrigerated (2–8 °C) and use within 30 days. Keep away from direct light and extreme temperatures.
- Does AOD-9604 ship with a Certificate of Analysis?
- Yes. Every batch of every product ships with a Certificate of Analysis from Freedom Diagnostics, an independent third-party analytical laboratory. The COA documents HPLC purity, peptide identity, endotoxin testing, and heavy-metals screening.
- Is AOD-9604 sold for human use?
- No. All products sold by Peptide Foundry are strictly for in-vitro research and laboratory use only (RUO). They are not intended for human or animal consumption, therapeutic use, or diagnostic application.
Scientific References
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PubMed: 11713213
- Ng FM, et al. Growth hormone treatment of hypophysectomized rats increases the secretion of insulin-like growth factor-I. Endocrinology. 2000;141(8):3098-3103. PubMed: 10965879
- Munro S, et al. AOD9604, a synthetic lipolytic peptide with high receptor binding affinity and in vivo efficacy. International Journal of Obesity. 2006;30(8):1217-1224.
This product is sold strictly for in-vitro research use only (RUO). It is not intended for human or animal consumption, therapeutic use, or diagnostic application.